Stock Ratings / Health Care / GLSI / financials

BCYC (20) LRMR (34) AMRN (32) ABEO (23) ⌘ Pro Terminal →

Greenwich LifeSciences Inc. (GLSI) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$17.41 -8.37% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $17.11

Greenwich LifeSciences Inc. (GLSI) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $255.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on GLSI Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is GLSI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Greenwich LifeSciences Inc. (NASDAQ: GLSI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $17.41 (-8.37% 1D, market cap $255.5M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, GLSI ranks #760 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does GLSI compare to BCYC and LRMR in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GLSI carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BCYC (Bicycle Therapeutics plc) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $256.5M) and LRMR (Larimar Therapeutics Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $256.6M). Among the 5-stock peer group, GLSI leads on earnings multiple (N/A) while AMRN leads on capital efficiency (-12.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for GLSI?

▼

Per GLSI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001799788), Greenwich LifeSciences Inc. generated $0 in revenue, -$19.4M in net income, and -$9.9M in free cash flow against $6.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $17.11 (-1.70%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-12.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GLSI)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (31/100 Composite)

🔍 WHY GLSI SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (32% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Whale & Options Positioning+7/20 pts (23% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$15.50+4.8% Next Q

Q2 (-2Q)

Grade E$16.24+7.3% Next Q

Q3 (-1Q)

Grade E$17.42-0.1% Next Q

Current

Grade E$17.41-9.4% Hist 90D α

Trajectory: E (23) → E (31)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a GLSI Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While GLSI currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($16.80) and Max Pain ($18.28) forces dealer call-delta covering toward $35.80.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $GLSI• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “GLSI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 31%NO 69%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How GLSI Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $4.00B

FY24

Rev $4.00B

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	-0.5%	-$19.4M	-$9.9M	-45%
FY 2024	$4.00B	52%	-0.4%	-$17.4M	-$7.3M	-45%
FY 2023	$4.00B	52%	-0.2%	-$8.9M	-$6.5M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GLSI)

✓Walkthrough of GLSI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

GLSI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -20.79%▼ DESCENDING CHANNEL

2026-11-03O $19.00H $19.00L $17.41C $17.41VOL 174.7K

RES: $19.31SUP: $13.97SMA50: $16.80SMA200: $21.46

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GLSI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 GLSI Butterfly Map → + Track GLSI →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on GLSI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for GLSI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for GLSI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GLSI)

Health Care Rank #760 of 1016 ⚔️ BCYC vs GLSI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (GLSI vs. BCYC, LRMR, AMRN, ABEO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Greenwich LifeSciences Inc. (GLSI) ranks #760 by composite RQD confidence (31/100, grade E) and #538 by equity capitalization ($255.5M). Within this direct 5-issuer industry benchmark cohort, GLSI leads on earnings valuation at N/A trailing P/E, while AMRN leads on capital efficiency and profitability with -12.2% ROIC and 56.6% gross margin. LRMR currently holds the highest overall quantitative score in the immediate peer group at 34/100 (E) compared with GLSI at 31/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
GLSI ACTIVE Greenwich LifeSciences Inc.	E	31/100	—	—	-35.0%	-8.37%	$255.5M	Benchmark Subject
BCYC Bicycle Therapeutics plc	E	20/100	—	—	-35.0%	-4.19%	$256.5M	/bcyc-vs-glsi →
LRMR Larimar Therapeutics Inc.	E	34/100	—	—	-35.0%	-7.49%	$256.6M	/lrmr-vs-glsi →
AMRN Amarin Corporation plc	E	32/100	—	56.6%	-12.2%	-4.91%	$249.9M	/amrn-vs-glsi →
ABEO Abeona Therapeutics Inc.	E	23/100	—	73.7%	-35.0%	-4.61%	$248.8M	/abeo-vs-glsi →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001799788

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Greenwich LifeSciences Inc. (GLSI) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$19.4M, operating cash flow of -$9.9M, and free cash flow of -$9.9M (-36.4% YoY). On the balance sheet, GLSI closed FY2025 with $6.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$19.4M	-$9.9M	-$9.9M	$6.2M	—
FY2024 (FY)	2024-12-31	$0	-$17.4M	-$7.3M	-$7.3M	$4.1M	—
FY2023 (FY)	2023-12-31	$0	-$8.9M	-$6.5M	-$6.5M	—	—

3. GLSI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GLSI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does GLSI compare to BCYC and LRMR in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for GLSI?

Where is GLSI trading relative to its 50-day, 200-day, and 52-week technical levels?

GLSI last traded at $17.41 (-8.37% on volume of 174,665 shares), positioning the stock +3.63% above its 50-day simple moving average ($16.80) and -18.87% below its 200-day simple moving average ($21.46). Across its 52-week range of $7.78 to $34.10, GLSI sits at the 36.6% percentile with a 14-day RSI of 51.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($15.23 to $19.59).

GLSI Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Greenwich LifeSciences Inc. (GLSI)?

In FY 2025 (10-K), GLSI converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: GLSI RQD Cockpit GLSI 12M Forecast GLSI Earnings & Move GLSI Dividends & DRIP GLSI Insiders & 13F GLSI Whale Options GLSI Profit Sankey GLSI News & Why

Sector Peer Dials

Compare →

BCYC E

Bicycle Therapeutics plc

20 /100

LRMR E

Larimar Therapeutics Inc.

34 /100

AMRN E

Amarin Corporation plc

32 /100

ABEO E

Abeona Therapeutics Inc.

23 /100

CAMP E

CAMP4 Therapeutics Corporation

GLSI Core Snapshot

Market Cap $255.5M

Trailing / Fwd P/E — / —

Gross Profit Margin —

Return on Capital (ROIC) -35.0%

Free Cash Flow Yield -3.55%

12M Base Price Target $15.29

FREE TRADER TOOLS

Own GLSI Alongside Other Stocks? Run a 30-Second Crash X-Ray

Drop 3–5 tickers into our live Portfolio X-Ray to spot hidden accounting time-bombs and see your composite RQD dial.

⚡ X-Ray My Portfolio With GLSI → 🏆 Trade GLSI in $100K Prop Arena →

GLSI Wire

Why It Moved →

Direct Company Event StockInvest.us • 18h ago

Greenwich Lifesciences Stock Price Forecast. Should You Buy GLSI?

Direct Company Event TradingView • 21h ago

Greenwich LifeSciences, Inc. Estimates – NASDAQ:GLSI

Peer / Ecosystem Wire Stock Titan • 1d ago

Greenwich LifeSciences, Inc. SEC Filing (Oct 26, 2026)

Direct Company Event Stock Traders Daily • 1d ago

Precision Trading with Greenwich Lifesciences Inc. (GLSI) Risk Zones

Peer / Ecosystem Wire Yahoo Finance Singapore • 1d ago

SELLAS Life Sciences Group, Inc. (SLS) stock price, news, quote and history

ROARABLE RATING BRIEF • RQD 31/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

GLSI — Greenwich LifeSciences Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:39:17Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, GLSI scores 35 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars: the Fundamental Cash Engine scores 6/20 (ROIC of -35% and FCF yield of -3.55%), indicating the business is currently consuming rather than generating cash on a return basis. Whale/13F Flow scores 10/20, reflecting institutional accumulation and options positioning that is moderate rather than decisive. Insider Conviction scores 3/20 on SEC Form 4 and Congressional PTR cluster flow, the weakest pillar and a signal of limited insider-side confidence per this rating. Macro Regime Fit scores 6/20 with a beta of 1.0 and sector sensitivity. Forensic Balance Sheet scores 10/20, based on an Altman Z of 2.5, a Piotroski F of 2/9, and a Debt/Equity of 0.5.

For a prospective investor evaluating the stock today, the upside case rests on the stock's recent price strength and the sector's sensitivity to pipeline or regulatory developments, which the source data does not quantify. The valuation tradeoff is stark: the company reports no revenue, negative operating income, and negative free cash flow across the reported periods, so there is no earnings base against which to anchor valuation. The rating's weakest signals (insider flow and cash generation) suggest the risk of further dilution or capital need is a central consideration, though the source data does not confirm financing plans.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-19.4M	$-19.4M	N/A	$-9.9M	$6.2M	N/A
FY 2024	$0.0M	$-17.6M	$-17.4M	N/A	$-7.3M	$4.1M	N/A
FY 2023	$0.0M	$-9.3M	$-8.9M	N/A	$-6.5M	N/A	N/A

Per the SEC financials, operating and net losses widened from $-9.3M (FY 2023 operating income) to $-19.4M (FY 2025). Gross, operating, and net margins are each reported as 0% in the market data, consistent with the absence of revenue. Per the market data, ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9. Reported cash rose from $4.1M to $6.2M over FY 2024–FY 2025, while Debt/Equity is 0.5 per the rating.

Recent Catalysts & News Wire Analysis

Per the recent news feed, there are six items tied to GLSI. Four are tagged "MARKET WIRE" (yellow): a StockInvest.us forecast article, a TradingView estimates item, a Stock Titan SEC filing notice dated Oct 26, 2026, and a Yahoo Finance Singapore listing item. One is tagged "RISK WATCH" (red): a Stock Traders Daily risk-zone piece. One Stock Titan item reports that CEO Snehal Patel's 2025 compensation totaled $6M. The feed headlines are generic market commentary; the source data does not describe the substance of the SEC filing or any specific clinical or regulatory catalyst. Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals.

Open Questions

What is the company's product pipeline and stage of development, given no revenue is reported?
What are the cash runway and financing plans, given FY 2025 cash of $6.2M against FY 2025 FCF of $-9.9M?
What is the substance of the October 26, 2026 SEC filing referenced in the news feed?
What are the debt terms, since Debt is recorded as N/A while Debt/Equity is 0.5 per the rating?
What drove the 52-week range from $7.78 to $34.1, and what is the current share count underlying the $278.9M market capitalization?

GLSI Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Greenwich LifeSciences Inc. (GLSI) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to GLSI Debate Forum (3) ↓

🟡 MARKET WIRE StockInvest.us • 18h ago

Greenwich Lifesciences Stock Price Forecast. Should You Buy GLSI?

StockInvest.us report covering Greenwich LifeSciences Inc. (GLSI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 21h ago

Greenwich LifeSciences, Inc. Estimates – NASDAQ:GLSI

TradingView report covering Greenwich LifeSciences Inc. (GLSI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Greenwich LifeSciences, Inc. SEC Filing (Oct 26, 2026)

Stock Titan report covering Greenwich LifeSciences Inc. (GLSI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Stock Traders Daily • 1d ago

Precision Trading with Greenwich Lifesciences Inc. (GLSI) Risk Zones

Stock Traders Daily report covering Greenwich LifeSciences Inc. (GLSI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance Singapore • 1d ago

SELLAS Life Sciences Group, Inc. (SLS) stock price, news, quote and history

Yahoo Finance Singapore report covering Greenwich LifeSciences Inc. (GLSI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

CEO Snehal Patel’s 2025 compensation totaled $6M at Greenwich LifeSciences (GLSI).

Stock Titan report covering Greenwich LifeSciences Inc. (GLSI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Kalkine Media • 1d ago

Greenwich LifeSciences Announces Annual Meeting for December 18, 2026, Featuring Key Board and Auditor Votes

Kalkine Media report covering Greenwich LifeSciences Inc. (GLSI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

BIOA Stock Price and Chart — NASDAQ:BIOA

TradingView report covering Greenwich LifeSciences Inc. (GLSI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

GLSI Bull vs. Bear Conversation Board — What's Your Call at $17.41?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON GLSI 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $16.72 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is GLSI (D- • RQD 35/100) a Buy at $19.00?

Welcome to the GLSI (Greenwich LifeSciences Inc.) Roar Pit. Current RQD Composite is 35/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $15.20 (-20.0%)

Spot @ $19.00

Pump the brakes on GLSI — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on GLSI, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Greenwich LifeSciences Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH 🎯 Target: $23.37 (+23.0%)

Spot @ $19.00

GLSI cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on GLSI, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $19.00 (52-wk range $7.78 - $34.10), any beat on forward guidance forces shorts and underweight funds to chase.